News
List of company announcements and press releases.
Click here for announcements regarding managers transactions.
Click here for news in Danish.
December 23, 2022 | Company Announcements
Bavarian Nordic Enters Agreement Valued up to USD 83 Million with the U.S. Department of Defense to Further Advance the Development of Equine Encephalitis Virus VaccineDecember 08, 2022 | Company Announcements
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic November 23, 2022 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseNovember 17, 2022 | Company Announcements
Bavarian Nordic Enters Joint Procurement Agreement with the European Health Emergency Preparedness and Response Authority (HERA) for Monkeypox VaccinesNovember 09, 2022 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2022October 17, 2022 | Company Announcements
Bavarian Nordic’s COVID-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial September 20, 2022 | Company Announcements
Luc Debruyne Appointed as Observer to the Board of Directors of Bavarian Nordic September 20, 2022 | Company Announcements
Bavarian Nordic Awarded Ten-Year Contract Amendment valued up to USD 434 million for the Supply of Smallpox and Monkeypox Vaccine to CanadaSeptember 07, 2022 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseSeptember 07, 2022 | Company Announcements
Bavarian Nordic Enters Additional Monkeypox Vaccine Supply Contract with the European Health Emergency Preparedness and Response Authority (HERA) September 02, 2022 | Company Announcements
Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine CandidateAugust 24, 2022 | Company Announcements
Bavarian Nordic Announces First Half 2022 ResultsAugust 23, 2022 | Company Announcements
Elizabeth McKee Anderson Resigns from the Board of Directors of Bavarian Nordic August 03, 2022 | Company Announcements
Bavarian Nordic Enters Additional Contract with APAC Country for Supply of Smallpox/Monkeypox Vaccine in 2023 July 22, 2022 | Company Announcements
Bavarian Nordic Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox July 19, 2022 | Company Announcements
Bavarian Nordic Secures Significant European Smallpox/Monkeypox Vaccine Order for 2023 July 18, 2022 | Company Announcements
Bavarian Nordic Enters Multiple Vaccine Contracts with Governments in Response to Global Monkeypox OutbreakJuly 15, 2022 | Company Announcements
U.S. Government Orders Another 2.5 Million Doses of Monkeypox Vaccines from Bavarian Nordic July 01, 2022 | Company Announcements
U.S. Government Orders Additional Monkeypox Vaccines from Bavarian Nordic June 14, 2022 | Company Announcements
Bavarian Nordic Enters Vaccine Supply Contract with the European Health Emergency Preparedness and Response Authority (HERA) in Response to Monkeypox Outbreak June 10, 2022 | Company Announcements
Bavarian Nordic Receives an Additional Order for JYNNEOS Smallpox and Monkeypox Vaccine from the U.S. Government June 07, 2022 | Company Announcements
Bavarian Nordic Enters a New Multi-Year Vaccine Contract with the Government of CanadaMay 30, 2022 | Company Announcements
Bavarian Nordic Enters Additional Vaccine Contracts with Governments in Response to Monkeypox OutbreakMay 25, 2022 | Company Announcements
Bavarian Nordic Enters First Larger Vaccine Contract with Government in Response to Monkeypox OutbreakMay 23, 2022 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise